CDHR18P: A Potential Drug Target and Biomarker for the Treatment of Cancer

Target Name: CDHR18P

NCBI ID: G100130345

CDHR18P

Other Name(s): Uncharacterized LOC100130345 | cadherin related family member 18, pseudogene | LOC100130345

CDHR18P: A Potential Drug Target and Biomarker for the Treatment of Cancer

Cancer is one of the leading causes of morbidity and mortality worldwide, with over 38 million new cases and 21 million cancer-related deaths in 2020, according to the World Health Organization (WHO). The development of new treatments and biomarkers for cancer has become a major focus in the fight against this disease, and CDHR18P is one such promising candidate. In this article, we will explore CDHR18P and its potential as a drug target and biomarker for cancer treatment.

CDHR18P: The CDHR18P Protein

CDHR18P is a protein that is expressed in various tissues and organs, including the brain, lung, liver, and pancreas. It is a member of the cryptodermal gene family (CGF), which is characterized by the presence of a cryptodermal gene signature and the ability to produce a variety of unique proteins. CDHR18P is unique because it is able to form a complex with the protein p16INK4a, which is a known regulator of cell growth and survival.

The p16INK4a protein has been shown to play a role in various cellular processes, including cell growth, apoptosis (programmed cell death), and tissue repair. It is also a known driver of cancer, and has been linked to the development of various types of cancer, including breast, ovarian, and prostate cancer. In addition, p16INK4a has been shown to promote the growth and survival of cancer cells, and may contribute to the development of resistance to chemotherapy.

CDHR18P and p16INK4a

The relationship between CDHR18P and p16INK4a is complex and mutually beneficial. CDHR18P and p16INK4a have been shown to interact and form a complex in various cellular contexts, including cell lines, tissues, and organs. These interactions have been shown to promote the growth and survival of cancer cells, and may contribute to the development of cancer.

In addition, CDHR18P and p16INK4a have been shown to play a role in the regulation of cellular processes, including cell cycle progression, apoptosis, and angiogenesis (the formation of new blood vessels). These processes are important for the development and progression of cancer, and may be targeted by new treatments.

CDHR18P as a Potential Drug Target

The potential drug target for CDHR18P is its interaction with p16INK4a. p16INK4a has been shown to play a role in the regulation of cell growth, apoptosis, and angiogenesis, and is a known driver of cancer. By targeting p16INK4a, CDHR18P may be able to inhibit the growth and survival of cancer cells, and may be a useful target for cancer treatment.

One approach to targeting p16INK4a is through the use of small molecules, such as inhibitors or modulators. These molecules have been shown to interact with p16INK4a and prevent or reverse its effects on cell growth and survival. By using small molecules to target p16INK4a, researchers may be able to develop new treatments for cancer.

CDHR18P as a Potential Biomarker

CDHR18P may also be a useful biomarker for the diagnosis and monitoring of cancer. The expression of CDHR18P has been shown to be elevated in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that CDHR18P may be a useful biomarker for the detection

Protein Name: Cadherin Related Family Member 18, Pseudogene

The "CDHR18P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDHR18P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets